| (Values in U.S. Thousands) | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2019 | Dec, 2018 |
| Sales | 32,660 | 4,950 | 4,250 | 0 | 0 |
| Sales Growth | +559.80% | +16.47% | unch | unch | unch |
| Net Income | -240 | -63,650 | -83,730 | -70,180 | -45,140 |
| Net Income Growth | +99.62% | +23.98% | -19.31% | -55.47% | -19.10% |
Erytech Pharma ADR (ERYP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Erytech Pharma S.A. operates as a biopharmaceutical company. It discovers and developes therapies for rare forms of cancer and orphan diseases. The company's product pipeline consists of eryaspase, erymethionase, eryminase, ERYZYME and ERYMMUNE which are in clinical stages. It operates primarily in France and the United States. Erytech Pharma S.A. is based in France.